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Abstract
Background: Nanoparticles are under investigation as carrier systems for anticancer drugs. The expression of efflux transporters
such as the ATP-binding cassette (ABC) transporter ABCB1 is an important resistance mechanism in therapy-refractory cancer
cells. Drug encapsulation into nanoparticles has been shown to bypass efflux-mediated drug resistance, but there are also
conflicting results. To investigate whether easy-to-prepare nanoparticles made of well-tolerated polymers may circumvent trans-
porter-mediated drug efflux, we prepared poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and PEGylated PLGA
(PLGA-PEG) nanoparticles loaded with the ABCB1 substrate doxorubicin by solvent displacement and emulsion diffusion ap-
proaches and assessed their anticancer efficiency in neuroblastoma cells, including ABCB1-expressing cell lines, in comparison to
doxorubicin solution.
Results: The resulting nanoparticles covered a size range between 73 and 246 nm. PLGA-PEG nanoparticle preparation by solvent
displacement led to the smallest nanoparticles. In PLGA nanoparticles, the drug load could be optimised using solvent displace-
ment at pH 7 reaching 53 µg doxorubicin/mg nanoparticle. These PLGA nanoparticles displayed sustained doxorubicin release
kinetics compared to the more burst-like kinetics of the other preparations. In neuroblastoma cells, doxorubicin-loaded PLGA-PEG
nanoparticles (presumably due to their small size) and PLGA nanoparticles prepared by solvent displacement at pH 7 (presumably
due to their high drug load and superior drug release kinetics) exerted the strongest anticancer effects. However, nanoparticle-
encapsulated doxorubicin did not display increased efficacy in ABCB1-expressing cells relative to doxorubicin solution.
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Conclusion: Doxorubicin-loaded nanoparticles made by different methods from different materials displayed substantial discrepan-
cies in their anticancer activity at the cellular level. Optimised preparation methods resulted in PLGA nanoparticles characterised
by increased drug load, controlled drug release, and high anticancer efficacy. The design of drug-loaded nanoparticles with opti-
mised anticancer activity at the cellular level is an important step in the development of improved nanoparticle preparations for
anticancer therapy. Further research is required to understand under which circumstances nanoparticles can be used to overcome
efflux-mediated resistance in cancer cells.
Introduction
According to Globocan, there “were 14.1 million new cancer
cases, 8.2 million cancer deaths and 32.6 million people living
with cancer (within five years of diagnosis) in 2012 worldwide”
[1]. Despite substantial improvements over recent decades, the
prognosis for many cancer patients remains unacceptably poor.
In particular, the outlook is grim for patients that are diagnosed
with disseminated (metastatic) disease who cannot be success-
fully treated by local treatment (surgery, radiotherapy). These
patients depend on systemic drug therapy. However, the thera-
peutic window is small, and anticancer therapies are typically
associated with severe side-effects [2,3].
One strategy to develop more effective cancer therapies is to
use nano-sized drug delivery systems that mediate a more spe-
cific tumour accumulation of transported drugs. Tumour target-
ing can be achieved via the enhanced permeability and reten-
tion (EPR) effect, which is the consequence of increased leaki-
ness of the tumour vasculature and a lack of lymph drainage
[4]. Nano-sized drug carrier systems can also prolong the circu-
lation time of anticancer drugs, protect them from degradation,
and sustain therapeutic drug concentrations due to prolonged/
controlled drug release. In addition, nanoparticles can be used
to administer poorly soluble agents, as demonstrated for nab-
paclitaxel, a HSA nanoparticle-based paclitaxel preparation ap-
proved for the treatment of different forms of cancer [4-9].
Another important aspect of the efficacy of nanoparticles as
delivery system for anticancer is their uptake and, in turn, the
drug transport into cancer cells. Uptake mechanisms may differ
between different types of nanoparticles, which may affect their
effectiveness as carriers for anticancer drugs. Here, we pre-
pared and directly compared the effects of doxorubicin-loaded
polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA)
nanoparticles in neuroblastoma cells. PLA and PLGA are well-
known ingredients of FDA- and EMA-approved drugs for
human use [10,11] and are easily degraded into their monomers,
lactic acid and glycolic acid. Furthermore, a copolymer
composed of polyethylene glycol (PEG) and PLGA (PLGA-
PEG) was used for nanoparticle preparation. PEGylated
(“stealth”) nanoparticles display prolonged systemic circulation
time, because they avoid agglomeration, opsonisation, and
phagocytosis [12].
In previous studies PLA-, PLGA-, PLA-PEG-, and PLGA-
PEG-based nanometre-sized drug carriers loaded with or cova-
lently linked to doxorubicin have been prepared by methods in-
cluding emulsion diffusion, solvent displacement, micelle for-
mation, and film rehydration followed by pH-gradient method
[13-19].
The expression of ATP-binding cassette (ABC) transporters
such as ABCB1 (also known as MDR1 or P-glycoprotein/P-gp),
which efflux a range of anticancer drugs, is an important drug
resistance mechanism in cancer cells [20,21]. Different nano-
sized drug carrier systems including PLA-, PLGA-, and PEG-
based preparations have been reported to bypass the transporter-
mediated efflux of anticancer drugs including doxorubicin
[20,22-31]. However, there are also conflicting results from
studies in which encapsulation of anticancer drugs into nano-
particles did not result in increased efficacy in ABCB1-
expressing cancer cells relative to drug solution [19,32,33].
Hence, systematic studies are required to better understand the
prospects and limitations of nanoparticles as carriers for anti-
cancer drugs, in particular in the context of efflux-mediated
resistance.
Since nanoparticles prepared by simple methods have the
highest chance of clinical translation, doxorubicin was incorpo-
rated into nanoparticles prepared from PLA, PLGA, and PLGA-
PEG by emulsion diffusion or solvent displacement approaches,
two well-established and comparatively simple preparation
methods. The resulting nanoparticles were compared by parti-
cle diameter, polydispersity index, zeta potential, drug load, and
drug release behaviour. Preliminary results on the preparation
of doxorubicin-loaded PLGA nanoparticles have been previ-
ously published [34]. Selected preparations were tested for anti-
cancer efficacy in cancer cell lines, including cell lines that
express ABCB1.
Results and Discussion
Influence of the preparation technique on
particle diameter and polydispersity index
Nanoparticles based on poly(lactic-co-glycolic acid) (PLGA), a
copolymer composed of polyethylene glycol (PEG) and PLGA
(PLGA-PEG) and polylactic acid (PLA), respectively, were pre-
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pared in the presence of doxorubicin by either emulsion diffu-
sion or solvent displacement technique. The resulting particle
diameters are presented in Figure 1.
Figure 1: Resulting particle diameters and loading efficiencies for dif-
ferent nanoparticle formulations using emulsion diffusion (ED) or sol-
vent displacement (SD) techniques (data expressed as means ± SD,
n ≥ 3).
Emulsion diffusion (173.5 ± 5.9 nm) and solvent displacement
(179.4 ± 7.6 nm) resulted in PLGA nanoparticles with similar
diameters. In contrast, solvent displacement resulted in PLGA-
PEG nanoparticles of 72.6 ± 3.3 nm whereas emulsion diffu-
sion resulted in PLGA-PEG nanoparticles of 222.6 ± 3.1 nm. In
accordance, solvent displacement using the stabiliser PVA at
concentrations between 2% and 4% (w/v) and controlled injec-
tion at mild stirring had previously been shown to produce
PLGA-PEG nanoparticles with a diameter below 100 nm [35-
37]. The hydrophilic PEG chains may sterically stabilise the
nanoparticles by reducing PLGA aggregation during nanoparti-
cle formation resulting in smaller particle diameters [38].
Emulsion diffusion resulted in PLA nanoparticles of
246.2 ± 2.9 nm and solvent displacement in PLA nanoparticles
of 192.1 ± 2.5 nm. The detailed reason for this is not clear, but
in the case of the emulsion diffusion technique the resulting
particle size is mainly influenced by the droplet size during the
initial emulsification step. In principle, PLA nanoparticles can
be prepared at a range of sizes that is determined by parameters
including the preparation method, the exact polymer used, and
the encapsulated drug [39-42]. Optimisation is possible [39,42]
but was not subject of this study focused on the comparison of
different nanoparticle systems prepared by simple methods.
Polydispersity indices smaller than 0.1 indicated a monodis-
perse size distribution for all nanoparticle preparations.
Monodispersity and particle diameters were confirmed by scan-
ning electron microscopy (SEM) images (Figure 2).
Influence of the preparation technique on
loading efficiency and drug release
Loading efficiencies ranging from 25.5 ± 1.0% to 44.8 ± 5.8%
of the applied doxorubicin were detected in the different nano-
particle preparations as shown in Figure 1, resulting in drug
loads between 2.6 ± 0.2 µg doxorubicin/mg nanoparticle and
6.7 ± 0.3 µg doxorubicin/mg nanoparticle (Table 1).
Table 1: Nanoparticle (NP) yield and doxorubicin (Dox) drug load
results for nanoparticles prepared by either emulsion diffusion (ED) or
solvent displacement (SD) technique (data expressed as means ± SD,
n ≥ 3).






PLGA ED 3.3 ± 0.4 66.8 ± 7.2 6.7 ± 0.3
PLGA SD 8.5 ± 0.4 70.4 ± 3.0 5.1 ± 0.2
PLGA-PEG ED 4.2 ± 0.1 84.4 ± 1.8 3.0 ± 0.2
PLGA-PEG SD 7.6 ± 0.9 63.6 ± 7.4 4.1 ± 0.6
PLA ED 8.0 ± 1.0 79.6 ± 9.8 2.6 ± 0.2
PLA SD 5.3 ± 0.2 44.1 ± 1.8 6.3 ± 0.1
In the case of PLGA and PLGA-PEG nanoparticles, emulsion
diffusion and solvent displacement resulted in nanoparticles
with a similar drug load. In PLA nanoparticles, there was a sub-
stantial difference between the techniques (solvent displace-
ment: 6.3 ± 0.1 µg doxorubicin/mg nanoparticle, emulsion
diffusion: 2.6 ± 0.2 µg doxorubicin/mg nanoparticle) (Table 1).
The reasons underlying this difference are not clear, but emul-
sion diffusion has been considered of limited efficacy for the
encapsulation of hydrophilic drugs [43,44].
All nanoparticles displayed a similar drug release behaviour
characterised by an initial burst release (Figure 3), which is in
accordance to previous studies and may be caused by processes
including the release of drug adsorbed to the nanoparticles and/
or rapid drug diffusion through the particle matrix [15,39,45-
47].
PEGylated polymers may result in a more porous particle struc-
ture, which is caused by aqueous channels created by PEG
chains and anticipated to further increase the initial burst release
[48]. However, the burst release was not increased substantially
further using PLGA-PEG nanoparticles. A slight drop in the
doxorubicin concentration was noticeable in the medium of the
PLGA nanoparticles. This may be the consequence of doxoru-
bicin adsorption to BSA [49], which was added to simulate the
presence of plasma proteins, in combination with a slower post-
burst doxorubicin release compared to the other nanoparticle
systems. Such a burst release should be avoided, because it may
result in drug release shortly after i.v. application before the
Beilstein J. Nanotechnol. 2019, 10, 2062–2072.
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Figure 2: SEM images of nanoparticles using emulsion diffusion (ED) or solvent displacement (SD) preparation technique. (A) PLGA nanoparticles
ED, (B) PLGA nanoparticles SD, (C) PLGA-PEG nanoparticles ED, (D) PLGA-PEG nanoparticles SD, (E) PLA nanoparticles ED, (F) PLA nanoparti-
cles SD. Images were taken at 10,000× magnification.
Beilstein J. Nanotechnol. 2019, 10, 2062–2072.
2066
Figure 3: Doxorubicin (Dox) release profiles over 24 h for all nanopar-
ticle systems using (A) emulsion diffusion (ED) or (B) solvent displace-
ment (SD) preparation technique (data expressed as means ± SD,
n = 3).
Table 2: Resulting particle diameter, polydispersity index (PDI), and
zeta potential (ZP) for PLGA nanoparticles prepared by an unmodified
PVA solution and a PVA solution adjusted to pH 7 (data expressed as
means ± SD, n = 3).
PVA
solution
diameter [nm] PDI ZP [mV]
without pH
adjustment
177.9 ± 1.0 0.039 ± 0.031 −41.6 ± 2.0
pH 7 174.1 ± 2.8 0.057 ± 0.030 −43.8 ± 3.7
nanoparticles reach the desired site of drug action, e.g., the
tumour tissue [50].
To optimise the loading efficiency and drug release kinetics of
PLGA nanoparticles the pH value of the stabiliser solution used
during nanoparticle preparation was increased to 7. At this
pH value, doxorubicin exists in the more lipophilic deproto-
nated form [51]. The use of PVA solution at pH 7 had no influ-
ence on the nanoparticle characteristics such as particle diame-
ter, PDI, and zeta potential (Table 2).
However, loading efficiency and drug load increased. The drug
load raised from 6.7 ± 0.3 µg doxorubicin/mg nanoparticle
(44.8 ± 5.8% loading efficiency) without pH adjustment to
7.9 ± 0.8 µg doxorubicin/mg nanoparticle (60.2 ± 3.8% loading
efficiency) at pH 7. By increasing the amount of doxorubicin to
2 mg, the drug load of PLGA nanoparticles could be further en-
hanced (non-adjusted pH: 18.0 ± 3.2 µg doxorubicin/mg nano-
particle; pH 7: 31.6 ± 3.1 µg doxorubicin/mg nanoparticle, re-
spectively) (Figure 4).
Figure 4: Doxorubicin (Dox) drug load and loading efficiency for PLGA
nanoparticles (NPs) prepared using a PVA solution without pH adjust-
ment and a PVA solution adjusted to pH 7 (data expressed as means
± SD, n = 3).
Different amounts of doxorubicin did not change the loading
efficiency at pH 7. Using aqueous solutions instead of metha-
nol, we increased the doxorubicin amount during preparation to
5 mg and 7.5 mg per 50 mg PLGA. While 5 mg resulted in an
increase of the drug load to 52.5 ± 0.4 µg doxorubicin/mg nano-
particle, 7.5 mg doxorubicin did not result in a significant
further increase (54.4 ± 3.4 µg doxorubicin/mg nanoparticle)
(Figure 5A).
This was an improvement in drug load compared to a nanoparti-
cle preparation in the presence of 2 mg doxorubicin. However,
a further increase of doxorubicin resulted in unstable nanoparti-
cle systems, as indicated by increasing particle diameter and
polydispersity index (Figure 5B). The loading efficiency for
PLGA nanoparticles prepared at pH 7 with 5 mg doxorubicin
was higher than this for nanoparticles manufactured with
7.5 mg doxorubicin (50.6 ± 0.6% and 33.9 ± 0.5%, respective-
ly). These loading efficiencies are in the range of those de-
scribed for similar preparations, although higher drug loads
have been described when using alternative PLGA-based
formulations such as nanoparticles or micelles with doxoru-
bicin covalently bound to the polymer, nanoparticles produced
by nanoprecipitation, micelles based on multi-arm star-shaped
PLGA–PEG block copolymers, or nanopolymersomes [14-18].
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Figure 5: (A) Drug load and loading efficiencies as well as (B) particle
diameter and PDI for different amounts of doxorubicin (Dox) used for
the preparation of PLGA nanoparticles by emulsion diffusion tech-
nique (data expressed as means ± SD, n = 3).
In addition, PLGA nanoparticles prepared at pH 7 displayed a
more controlled and sustained doxorubicin release than PLGA
nanoparticles prepared without pH adjustment (Figure 6).
Hence, PLGA nanoparticles prepared at pH 7 with 5 mg
doxorubicin were selected for cell culture experiments.
Figure 6: Release profiles of doxorubicin from PLGA nanoparticles
prepared using an unmodified PVA solution and a PVA solution
adjusted to pH 7 (data expressed as means ± SD, n = 3).
The different release kinetics from PLGA nanoparticles pre-
pared at pH 7, may be attributed to the higher lipophilicity of
doxorubicin at this pH value and, in turn, a stronger incorpora-
tion into the lipophilic PLGA nanoparticle matrix. This expla-
nation is consistent with data showing that PLGA nanoparticle
degradation is unlikely to occur in a 24 h timeframe [50,52].
More sustained release patterns have been shown to be achiev-
able by alternative nanoparticle approaches based on PLGA
such as nanoparticles or micelles with doxorubicin covalently
bound to the polymer, nanoparticles produced by nanoprecipita-
tion, micelles based on multi-arm star-shaped PLGA–PEG
block copolymers, or nanopolymersomes [14-18].
Nanoparticle efficacy in cell culture
Finally, the effects of doxorubicin-loaded PLA nanoparticles
prepared by solvent displacement (because they were smaller
and the drug load was higher compared to those prepared by
emulsion diffusion), PLGA nanoparticles prepared by solvent
displacement at a non-adjusted pH value and at pH 7, and
PLGA-PEG nanoparticles prepared by emulsion diffusion and
solvent displacement were tested for their effects on the
viability of the neuroblastoma cell line UKF-NB-3, its doxoru-
bicin-adapted sub-line UKF-NB-3rDOX20, and its vincristine-
resistant sub-line UKF-NB-3rVCR1. In all three cell lines, PLA
nanoparticles, PLGA nanoparticles prepared by solvent dis-
placement at a non-adjusted pH value, and PLGA-PEG nano-
particles prepared by emulsion diffusion displayed reduced effi-
cacy compared to doxorubicin solution (Figure 7).
In contrast, PLGA nanoparticles prepared by solvent displace-
ment at pH 7 and PLGA-PEG nanoparticles prepared by sol-
vent displacement were similarly active as free doxorubicin
(Figure 7). The corresponding empty nanoparticles did not
affect cell viability in the tested concentrations.
The main difference between the doxorubicin-loaded PLGA-
PEG nanoparticles prepared by solvent displacement and the
other preparations is the size. It is the only preparation in which
nanoparticles have a size clearly smaller than 100 nm
(72.6 ± 3.3 nm, Figure 1). This might indicate that the cellular
uptake of smaller nanoparticles is higher than that of larger
nanoparticles, which is coherent with previous findings
showing that cellular uptake of nanoparticles decreases with an
increase of size [53]. PLGA nanoparticles prepared by solvent
displacement at pH 7 displayed the highest drug load. Hence,
their superior effects may be explained by an increased drug
transport per nanoparticle into cancer cells.
Nano-sized drug carriers have been shown to bypass efflux-
mediated drug resistance [25]. This included various nanoparti-
cle and liposome formulations of the ABCB1 substrate doxoru-
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Figure 7: Doxorubicin concentrations that reduce neuroblastoma cell
viability by 50% (IC50) when administered encapsulated into different
nanoparticle preparations (PLA-NP, PLA nanoparticles prepared by
solvent displacement; PLGA-NP, PLGA nanoparticles prepared by sol-
vent displacement at a non-adjusted pH value; PLGA-NPpH7, PLGA
nanoparticles prepared by solvent displacement at pH 7; PLGA-PEG-
ED, PLGA-PEG nanoparticles prepared by emulsion diffusion; PLGA-
PEG-SD, PLGA-PEG nanoparticles prepared by solvent displacement)
compared to doxorubicin solution (doxorubicin). Unloaded nanoparti-
cles did not affect cell viability in the tested concentration range.
*IC50 > 500 ng/mL.
bicin that were shown to modify the cellular uptake and intra-
cellular distribution of doxorubicin resulting in enhanced effects
against ABCB1-expressing cancer cells, when compared to free
doxorubicin in solution [26-31]. The doxorubicin-adapted UKF-
NB-3 sub-line UKF-NB-3rDOX20 is characterised by high
ABCB1 expression [54]. In addition, the vincristine-resistant
UKF-NB-3 sub-line UKF-NB-3rVCR1 displays cross-resis-
tance to doxorubicin and becomes sensitised to doxorubicin by
the specific ABCB1 inhibitor zosuquidar (Figure 8). This indi-
cates that drug resistance is at least in part mediated by ABCB1
in this cell line. However, free doxorubicin solution and
doxorubicin bound to PLGA-PEG nanoparticles prepared by
solvent displacement or PLGA nanoparticles prepared by sol-
vent displacement at pH 7 displayed similar efficacy in UKF-
NB-3rDOX20 and UKF-NB-3rVCR1 cells (Figure 7). Hence,
these drug carrier systems are not able to overcome transporter-
mediated drug resistance. One reason for this may be that the
doxorubicin burst release kinetics observed for these nanoparti-
cles do not enable a sufficient bypassing of transporter-medi-
ated drug efflux. However, PLGA nanoparticles prepared by
solvent displacement at pH 7 did not display improved efficacy
in ABCB1-expressing cells despite improved drug release
kinetics. Possibly, other PLGA-based preparations, which
display more sustained drug release, such as nanoparticles or
micelles with doxorubicin covalently bound to the polymer,
nanoparticles produced by nanoprecipitation, micelles based on
multi-arm star-shaped PLGA–PEG block copolymers, or
nanopolymersomes [14-18] may overcome such limitations.
Figure 8: Doxorubicin concentrations that reduce UKF-NB-3rVCR1
viability by 50% (IC50) in the absence or presence of the ABCB1 inhib-
itor zosuquidar (1 µM). Zosuquidar did not affect cell viability when
administered alone.
Conclusion
In this study, we synthesised a range of doxorubicin-loaded
PLA- and PLGA-based nanoparticle systems using emulsion
diffusion and solvent displacement approaches. Our results
show that particle size, loading efficiency, and drug release
kinetics can be controlled by the production procedure. Testing
of the nanoparticle preparations in the neuroblastoma cell line
UKF-NB-3 and its sub-lines with acquired resistance to doxoru-
bicin or vincristine indicated that smaller nanoparticles and a
high drug load result in nanoparticle preparations that have a
similar efficacy at the cellular level as doxorubicin solution. In
particular, doxorubicin-loaded PLGA-PEG nanoparticles pre-
pared by solvent displacement, which displayed the smallest di-
ameter, and PLGA nanoparticles prepared by solvent displace-
ment at pH 7, which displayed the highest drug load, exerted
the most pronounced anticancer effects, which were compa-
rable to doxorubicin solution. Since nanoparticle preparations
are known to have the capacity to improve the in vivo activity
of anticancer drugs by tumour targeting through the EPR effect,
this is an important step in the development of improved nano-
particle preparations. However, the investigated nanoparticle
preparations did not circumvent transporter-mediated drug
efflux. Hence, more research is required to identify drug carrier
systems that reliably bypass efflux-mediated drug resistance.
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Table 3: Preparation parameters for nanoparticles based on different polymers using emulsion diffusion technique.
polymer amount of polymer organic solvent homogenisation
PLGA 50 mg 2.5 mL ethyl acetate 15,000 rpm for 5 min
PLA 100 mg 2.0 mL dicholoromethane 18,000 rpm for 15 min
PLGA-PEG 50 mg 2.5 mL ethyl acetate 15,000 rpm for 5 min
Experimental
Reagents
PLGA (Resomer® RG502H), PLA (Resomer® R203H), and
PLGA-PEG (Resomer® RGP d 50155) were obtained from
Evonik Industries AG (Essen, Germany). Ethyl acetate,
dichloromethane, and methanol were purchased from VWR
International GmbH (Darmstadt, Germany). Acetone, aceto-
nitrile and dimethyl sulfoxide (DMSO) were obtained from Carl
Roth GmbH (Karlsruhe, Germany). Poly(vinyl alcohol) (PVA,
30,000–70,000 Da), bovine serum albumin (BSA), HSA, and
glutaraldehyde were obtained from Sigma-Aldrich Chemie
GmbH (Karlsruhe, Germany). Dulbecco's Phosphate buffered
saline (PBS) was purchased from Biochrom GmbH (Berlin,
Germany). Doxorubicin was obtained from LGC Standards
GmbH (Wesel, Germany). All chemicals were of analytical
grade and used as received.
Nanoparticle preparation via emulsion
diffusion
PLA and PLGA nanoparticles were prepared by a previously
described emulsion diffusion technique [35,55]. PLA, PLGA, or
PLGA-PEG were dissolved in organic solvents (Table 3) and
200 µL of a methanolic doxorubicin solution (2.5 mg/mL) was
added.
This solution was then poured into 5 mL (1%, m/v) PVA solu-
tion and afterwards homogenized with an Ultra Turrax (IKA-
Werke, Staufen, Germany) as indicated in Table 3. Subse-
quently this pre-emulsion was mixed with another 5 mL (1%,
m/v) PVA solution. After stirring overnight, the resultant nano-
particles were purified three times by centrifugation at 21,000g
for 15 min (Eppendorf Centrifuge 5430 R, Eppendorf,
Hamburg, Germany) and re-dispersion in purified water.
After the final purification step, an aliquot of the nanoparticle
suspension was centrifuged and the resulting pellet was dis-
solved in 1 mL DMSO in order to measure the entrapped
amount of doxorubicin by HPLC (see below).
In order to increase the drug load for PLGA nanoparticles dif-
ferent volumes of the methanolic doxorubicin solution
(2.5 mg/mL) were used corresponding to 1.0, 1.5, and 2.0 mg
total doxorubicin. For a further increase in drug load different
aqueous doxorubicin solutions (ranging from 10.0 to
50.0 mg/mL) were used to achieve total doxorubicin amounts of
0.5, 2.5, 5.0, 7.5, 12.5, and 25.0 mg. Here, the PLGA solution in
ethyl acetate was homogenized with the aqueous doxorubicin
solution and 5 mL (1%, m/v) PVA solution to achieve the pre-
emulsion. In all experiments to increase the drug load the
amount of the polymer was kept constant at 50 mg. To prepare
doxorubicin-loaded nanoparticles at a defined pH value of 7, a
PVA solution (1%, m/v) in phosphate buffer (15.6 mg/mL
NaH2PO4·2H2O; pH adjusted to pH 7 with NaOH) was used.
Nanoparticle preparation via solvent dis-
placement
Nanoparticle preparation via solvent displacement was per-
formed modified after Murakami et al. [13] as previously de-
scribed by Pieper and Langer [34]. 60 mg polymer were dis-
solved in 2 mL acetone and combined with 200 µL methanolic
doxorubicin solution (2.5 mg/mL). This mixture was injected
into 4 mL 2% (m/v) PVA solution to produce PLGA and
PLGA-PEG nanoparticles or into 4 mL 1% (m/v) PVA solution
to produce PLA nanoparticles. After stirring overnight at
550 rpm and evaporation of the organic solvent, PLA and
PLGA nanoparticles were purified three times by centrifuga-
tion at 21,000 g for 15 min and re-dispersion in purified water.
PLGA-PEG nanoparticles were purified three times by centrifu-
gation at 30,000g for 60 min and re-dispersion in purified
water.
Determination of particle size, size
distribution and zeta potential
Average particle size and the polydispersity were measured by
photon correlation spectroscopy (PCS) using a Malvern zeta-
sizer nano (Malvern Instruments, Herrenberg, Germany). The
resulting particle suspensions were diluted 1:100 with purified
water and measured at a temperature of 22 °C using a backscat-
tering angle of 173°. The zeta potential was determined with the
same instrument and the same diluted nanoparticle suspension
by laser Doppler microelectrophoresis.
Scanning electron microscopy (SEM)
For scanning electron microscopy (SEM), the particle suspen-
sions were diluted with purified water to 0.25 mg/mL. The
suspension was dripped on a filter (MF-Millipore™ membrane
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filter VSWP, 0.1 µm) and dried for 24 h in a desiccator. After-
wards, the membranes were sputtered with gold under argon at-
mosphere (SCD 040, BAL-TEC, Balzers, Liechtenstein). The
SEM pictures were received at an accelerating voltage of
10,000 V and a working distance of 10 mm (CamScan CS4,
Cambridge Scanning Company, Cambridge, UK).
Doxorubicin quantification via HPLC-UV
The amount of doxorubicin that had been incorporated into the
nanoparticles was determined by HPLC-UV (HPLC 1200
series, Agilent Technologies GmbH, Böblingen, Germany)
using a LiChroCART 250 × 4 mm LiChrospher 100 RP
18 column (Merck KGaA, Darmstadt, Germany). The mobile
phase was a mixture of water and acetonitrile (70:30) contain-
ing 0.1% trifluoroacetic acid [56]. In order to obtain symmetric
peaks a gradient was used. In the first 6 min the percentage of
water was reduced from 70% to 50%. Subsequently within
2 min the amount of water was further decreased to 20% and
then within another 2 min increased again to 70%. These condi-
tions were hold for a final 5 min resulting in a total runtime of
15 min. While using a flow rate of 0.8 mL/min, an elution time
for doxorubicin of t = 7.5 min was achieved. The detection of
doxorubicin was performed at a wavelength of 485 nm [57].
In vitro drug release studies
To study drug release in vitro, a nanoparticle suspension of
1 mg nanoparticles in 1 mL of PBS containing 5% (m/v) bovine
serum albumin (BSA) was shaken at 37 °C with 500 rpm.
Nanoparticle suspensions were centrifuged (30,000g, 15 min)
after 0, 0.5, 1, 2, 4, 6, 8, and 24 h, and an aliquot (250 µL) of
the supernatant was diluted with 750 µL ethanol (96%, v/v) in
order to precipitate BSA. After a second centrifugation step
(30,000g, 10 min) the supernatant was analysed for the amount
of released doxorubicin by HPLC as mentioned above. Addi-
tionally, the resulting pellet was dissolved in DMSO in order to
calculate doxorubicin recovery.
Cell culture
The MYCN-amplified neuroblastoma cell line UKF-NB-3 was
established from stage-4 neuroblastoma patients [54]. UKF-NB-
3 sub-lines adapted to growth in the presence of doxorubicin
20 ng/mL (UKF-NB-3rDOX20) [54] or vincristine 1 ng/mL
(UKF-NB-3rVCR1) were established by continuous exposure to
step-wise increasing drug concentrations as previously de-
scribed [54,58] and derived from the Resistant Cancer Cell Line
(RCCL) collection (https://research.kent.ac.uk/ibc/the-resistant-
cancer-cell-line-rccl-collection/).
All cells were propagated in Iscove’s modified Dulbecco’s me-
dium (IMDM) supplemented with 10% foetal calf serum,
100 U/mL penicillin and 100 mg/mL streptomycin at 37 °C.
The drug-adapted sub-lines were continuously cultured in the
presence of the indicated drug concentrations. Cells were
routinely tested for mycoplasma contamination and authenti-
cated by short tandem repeat profiling.
Cell viability assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay modified after
Mosmann [59], as previously described [55]. 2 × 104 cells
suspended in 100 µL cell culture medium were plated per well
in 96-well plates and incubated in the presence of various con-
centrations of drug or drug preparations for 120 h. Where indi-
cated, the ABCB1 inhibitor zosuquidar was added at a fixed
concentration of 1 µM. Then, 25 µL of MTT solution (1 mg/mL
(w/v) in PBS) were added per well, and the plates were incubat-
ed at 37 °C for an additional 4 h. After this, cells were lysed
using 200 µL of a buffer containing 20% (w/v) sodium dodecyl-
sulfate and 50% (v/v) N,N-dimethylformamide (pH 4.7) at
37 °C for 4 h. Absorbance was determined at 570 nm for each
well using a 96-well multiscanner. After subtracting of the
background absorption, the results are expressed as percentage
viability relative to untreated control cultures. Drug concentra-
tions that inhibited cell viability by 50% (IC50) were deter-
mined using CalcuSyn (Biosoft, Cambridge, UK).
Statistical methods
All experiments of nanoparticle preparation and characterisa-
tion were performed at least three times. The results are shown
as average value with standard deviation. Significance tests
were conducted with Sigma Plot 12.5 (Systat Software GmbH,
Erkrath, Germany), using a one-way ANOVA test with the
Holm–Sidak post test. Significance levels were depicted as *
for p ≤ 0.05, ** for p ≤ 0.01, and *** for p ≤ 0.001.
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